PACIFIC

NCT02125461 📎

Regimen

Experimental
durvalumab consolidation
Control
placebo

Population

Unresectable stage III NSCLC post-CRT

Key finding

mPFS 16.8 vs 5.6 mo HR 0.52 (0.42-0.65); mOS 47.5 vs 29.1 mo HR 0.72

Source: PMID 28885881

Timeline

  • Enrollment start: 2014-05-07 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.14)
  • CSCO NSCLC 2025 ⚠️ OCR source